secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2026-08-21T21:05:14+00:00
Accession:  0001213900-26-092672
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea gets Nasdaq 180-day extension to Feb 16, 2027 for bid-price rule
-------------------------------------------------------------------------

- Nasdaq notified Feb 20, 2026 of non-compliance with $1.00 minimum bid price rule 5550(a)(2).
- On Aug 20, 2026, Nasdaq granted 180-day extension to Feb 16, 2027 to regain compliance.
- Company may implement reverse stock split to cure; delisting and appeal rights if not cured.
- No assurance compliance will be achieved within the extension period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390026092672/0001213900-26-092672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390026092672/ea0302993-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-092672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer